Skip to main content

Table 3 Percentage changes in (geometric mean) PFAS concentrations as a function of visit and parity, estimated in a linear mixed model with adjustment for pre-pregnancy body mass index, maternal age, and batch number. The last column shows the p-value in test of the hypothesis for no differences between groups

From: Serum concentrations of per- and poly-fluoroalkyl substances (PFAS) in Danish pregnant women—temporal trends during pregnancy, correlations with partners, associations with physical activity, and blood lipid concentrations

PFAS

Covariate

Change [95% CI]

p-value

Overall p-value

PFOS

 

Visit

1a

0

 

 < 0.001

 

Visit

2

−6.28 [−11.74;−0.49]

0.034

 
 

Visit

3

−10.82 [−18.15;−2.84]

0.009

 
 

Visit

4

−23.14 [−31.92;−13.22]

 < 0.001

 
 

Parity

0a

0

 

0.078

 

Parity

1

−10.78 [−20.71;0.40]

0.058

 
 

Parity

2

−18.84 [−31.58;−3.73]

0.017

 
 

Parity

3

−12.53 [−39.04;25.53]

0.466

 

PFOA

 

Visit

1a

0

 

 < 0.001

 

Visit

2

−14.60 [−20.28;−8.51]

 < 0.001

 
 

Visit

3

−16.06 [−24.29;−6.95]

 < 0.001

 
 

Visit

4

−23.89 [−34.04;−12.19]

 < 0.001

 
 

Parity

0a

  

 < 0.001

 

Parity

1

−36.69 [−43.64;−28.88]

 < 0.001

 
 

Parity

2

−35.65 [−45.65;−23.82]

 < 0.001

 
 

Parity

3

−40.37 [−58.26;−14.81]

0.005

 

PFHxS

 

Visit

1a

0

 

0.065

 

Visit

2

−18.38 [−31.08;−3.35]

0.019

 
 

Visit

3

−14.69 [−33.23;8.99]

0.203

 
 

Visit

4

−21.56 [−43.88;9.63]

0.154

 
 

Parity

0a

0

 

 < 0.001

 

Parity

1

−34.69 [−43.73;−24.20]

 < 0.001

 
 

Parity

2

−48.35 [−58.43;−35.82]

 < 0.001

 
 

Parity

3

−39.49 [−61.48;−4.94]

0.030

 

PFNA

 

Visit

1a

0

 

 < 0.001

 

Visit

2

−11.23 [−17.69;−4.26]

0.002

 
 

Visit

3

−16.80 [−25.59;−6.97]

0.001

 
 

Visit

4

−35.22 [−44.58;−24.27]

 < 0.001

 
 

Parity

0a

0

 

0.251

 

Parity

1

−10.50 [−20.48;0.72]

0.066

 
 

Parity

2

−12.25 [−26.03;4.11]

0.133

 
 

Parity

3

−8.85 [−36.42;30.68]

0.613

 

PFDA

 

Visit

1a

0

 

0.005

 

Visit

2

−12.04 [−19.66;−3.70]

0.006

 
 

Visit

3

−8.04 [−19.24;4.73]

0.206

 
 

Visit

4

−18.42 [−31.91;−2.26]

0.027

 
 

Parity

0a

0

 

0.423

 

Parity

1

2.09 [−8.99;14.53]

0.723

 
 

Parity

2

9.85 [−7.00;29.76]

0.267

 
 

Parity

3

27.60 [−9.83;80.58]

0.168

 

PFUnDA

 

Visit

1a

  

0.253

 

Visit

2

−2.78 [−13.72;9.54]

0.642

 
 

Visit

3

−7.10 [−20.76;8.93]

0.363

 
 

Visit

4

−21.26 [−38.75;1.22]

0.062

 
 

Parity

0a

  

0.829

 

Parity

1

1.14 [−10.25;13.97]

0.852

 
 

Parity

2

7.79 [−10.03;29.14]

0.414

 
 

Parity

3

10.41[−23.16;58.64]

0.591

 
  1. Visit 1: Gestational age week 6 + 1 to 15 + 0
  2. Visit 2: Gestational age week 28 + 0–6
  3. Visit 3: Gestational age week 34 + 0–6
  4. Visit 4: Delivery, gestational age week 32 + 1 to 42 + 0
  5. PFAS per- and polyfluoroalkyl substances, PFOS perfluorooctane sulfonic acid, PFOA perfluorooctanoic acid, PFHxS perfluorohexane sulfonate, PFNA perfluorononanoic acid, PFDA perfluorodecanoic acid, PFUnDA perfluoroundecanoic acid
  6. aReference group